A. Bianco (Napoli, Italy), T. Cremona (Bern, Switzerland)
A Possible Complication of Chronic Obstructive Pulmonary Disease: Ischemic Colitis
S. Mauntana (El Paso, United States), M. Gajendran (San Antonio, United States)
|  |
Underdiagnosis of chronic obstructive pulmonary disease: a problem that persists
A. Roca Noval (Madrid, Spain), R. García García (Madrid, Spain), M. Jiménez Gómez (Madrid, Spain), J. Díaz Miravalls (Madrid, Spain), E. Catalinas Muñoz (Madrid, Spain)
|  |
Barriers to early diagnosis and smoking cessation for COPD patients
L. Belenko Gentet (Drucourt, France)
| |
Development in diagnosed comorbidities over a twelve-month period in patients with COPD
M. Brath (Aalborg, Denmark), S. Dyrman Alsted (Aalborg, Denmark), P. Veiss-Pedersen (Aalborg, Denmark), R. Brath Christensen (Aalborg, Denmark), U. Møller Weinreich (Aalborg, Denmark)
| |
COPD patients’ experiences and understanding of exacerbations: a qualitative study
M. Crooks (East Riding of Yorkshire, United Kingdom), R. Russell (Oxford, United Kingdom), H. Cummings (East Yorkshire, United Kingdom), K. Roy (London, United Kingdom), O. Usmani (London, United Kingdom), J. Cohen (Hull, United Kingdom), S. Macfadyan (London, United Kingdom), T. Morris (Luton, United Kingdom), H. Mullerova (Luton, United Kingdom), Y. Xu (Luton, United Kingdom), A. Hutchinson (East Riding of Yorkshire, United Kingdom)
| |
Undiagnosed and undertreated heart disease in hospitalised patients with exacerbations of chronic obstructive pulmonary disease (COPD)
J. Kibbler (North Shields, United Kingdom), D. Ripley (North Shields, United Kingdom), S. Bourke (North Shields, United Kingdom), J. Steer (North Shields, United Kingdom)
| |
Impact of treatment with inhaled corticosteroids on COVID-19 risk and outcome – a potential protective effect on severity of disease and survival
M. Labor (Linköping, Sweden), F. Nyberg (Gothenburg, Sweden), B. Kirui (Gothenburg, Sweden), L. Vanfleteren (Gothenburg, Sweden)
| |
Relationship between plasma alpha-1-antitrypsin polymers and lung or liver function in ZZ alpha-1-antitrypsin deficient patients
S. Tumpara (Hannover, Germany), S. Janciauskiene (Hannover, Germany), B. Olejnicka (Lund, Sweden), M. Fromme (Aachen, Germany), P. Strnad (Aachen, Germany), T. Welte (Hannover, Germany), J. Stolk (Leiden, Netherlands)
| |
Effectiveness of Nationwide COPD Pay-for- Performance Program on quality-of-life for COPD patients
C. Chen (Tainan, Taiwan), S. Tsai (Tainan, Taiwan)
| |
Risk of malignancy in patients with asthma-COPD overlap compared to patients with COPD without asthma
B. Bonnesen (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), A. Jordan (Hellerup, Denmark), J. Wirenfeldt Pedersen (Herlev, Denmark), C. Marisa Bergsøe (Hellerup, Denmark), J. Eklöf (Hellerup, Denmark), L. Lindhardt Toennesen (Hellerup, Denmark), S. Graff Jensen (Hellerup, Denmark), M. Naqibullah (Hellerup, Denmark), Z. Saghir (Hellerup, Denmark), J. Jensen (Hellerup, Denmark)
| |
Impact of moderate to severe asthma from the patient’s perspective in Spain
J. Dominguez-Ortega (Madrid, Spain), V. Plaza (Barcelona, Spain), J. Delgado Romero (Sevilla, Spain), A. Nieto (Valencia, Spain), J. Molina (Madrid, Spain), J. Ancochea (Madrid, Spain), A. Gil (Madrid, Spain), J. Oliva (Ciudad Real, Spain), M. Blanco-Aparicio (A Coruña, Spain), M. Sarasa (Barcelona, Spain)
| |
Outcomes after prolonged weaning in COPD patients – Data from the German WeanNet-Initiative
M. Wollsching-Strobel (Cologne, Germany), T. Freundt (Hanover, Germany), N. Hämäläinen (Hanover, Germany), S. Suchi (Hanover, Germany), W. Windisch (Cologne, Germany), B. Schönhofer (Bielefeld, Germany)
| |
Evaluation of risk factors for barotrauma complications in COVID-19 patients treated with high flow nasal cannula (HFNC)
P. Titorenkov (Sofia, Bulgaria), D. Manoylov (Sofia, Bulgaria), M. Encheva (Sofia, Bulgaria), S. Zabadanova (Sofia, Bulgaria), E. Naseva (Sofia, Bulgaria)
| |
Five-year all-cause hospitalizations in patients with COPD following their first-ever exacerbation-related hospitalization
K. Waeijen-Smit (Horn, Netherlands), P. Jacobsen (Aalborg, Denmark), S. Houben-Wilke (Horn, Netherlands), S. Simons (Maastricht, Netherlands), F. Franssen (Horn, Netherlands), M. Spruit (Horn, Netherlands), C. Pedersen (Hillerød, Denmark), K. Kragholm (Aalborg, Denmark), U. Weinreich (Aalborg, Denmark)
| |
Over-the-counter (OTC) short-acting ß2-agonist (SABA) purchase and asthma outcomes in SABINA III
H. Farouk (Dubai, United Arab Emirates), W. Mattarucco (Entre Rios, Argentina), R. Barriga (Chihuahua, Mexico), H. Wang (Taipei, Taiwan), D. Diaz (Manila, Philippines), A. Khattab (Cairo, Egypt), M. Gallego (Pereira, Colombia), A. Zaabi (Abu Dhabi, United Arab Emirates), D. Price (Aberdeen, United Kingdom)
| |
Severe eosinophilic asthma with paradoxal worsening T2 bronchial inflammation despite sequencial treatment with mepolizumab and benralizumab
C. Marcot (STRASBOURG, France), N. Khayath (STRASBOURG, France), F. De Blay (STRASBOURG, France), N. Migueres (Strasbourg, France)
| |
Three sensitization patterns to mugwort, timothy, birch and their main allergen components revealed by latent class analysis
W. Liting (Guangzhou, China), L. Wenting (Guangzhou, China), H. Haisheng (Guangzhou, China), Z. Xianhui (Guangzhou, China), C. Yuemin (Guangzhou, China), S. Baoqing (Guangzhou, China)
| |
Effect of positive airway pressure (PAP) therapy in patients with excessive dynamic airway collapse (EDAC)
N. Shah (London, United Kingdom), K. Jadeja (London, United Kingdom), M. Cheng (London, United Kingdom), P. Marino (London, United Kingdom), M. Ramsay (London, United Kingdom), S. Srivastava (London, United Kingdom), J. Steier (London, United Kingdom), N. Hart (London, United Kingdom), E. Suh (London, United Kingdom), P. Murphy (London, United Kingdom), G. Kaltsakas (London, United Kingdom)
| |
Nasal high flow oxygen therapy compared to conventional oxygen therapy in hospitalised patients with respiratory illness: a systematic review and meta-analysis
D. Seow (Singapore, Singapore), Y. Khor (Melbourne, Australia), S. Khung (Melbourne, Australia), D. Smallwood (Melbourne, Australia), Y. Ng (Melbourne, Australia), N. Smallwood (Melbourne, Australia)
| |
Extended-release morphine for chronic breathlessness in COPD: a randomized controlled trial with blinded up-titration over three weeks
M. Ekström (Lund, Sweden), D. Ferreira (Wollongong, Australia), S. Chang (Sydney, Australia), S. Louw (Sydney, Australia), M. Johnson (Hull, United Kingdom), D. Eckert (Adelaide, Australia), B. Fazekas (Sydney, Australia), K. Clark (Sydney, Australia), M. Agar (Sydney, Australia), D. Currow (Wollongong, Australia)
| |